238 related articles for article (PubMed ID: 9393758)
1. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
Gonzalgo ML; Bender CM; You EH; Glendening JM; Flores JF; Walker GJ; Hayward NK; Jones PA; Fountain JW
Cancer Res; 1997 Dec; 57(23):5336-47. PubMed ID: 9393758
[TBL] [Abstract][Full Text] [Related]
2. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
Merbs SL; Sidransky D
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):779-83. PubMed ID: 10067984
[TBL] [Abstract][Full Text] [Related]
3. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
Ryan A; Al-Jehani RM; Mulligan KT; Jacobs IJ
Gynecol Oncol; 1998 Jan; 68(1):14-7. PubMed ID: 9454653
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
5. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.
Fujimoto A; Morita R; Hatta N; Takehara K; Takata M
Oncogene; 1999 Apr; 18(15):2527-32. PubMed ID: 10229204
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A mutation and deletion status in thin and thick primary melanoma.
Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ
Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
Herman JG; Jen J; Merlo A; Baylin SB
Cancer Res; 1996 Feb; 56(4):722-7. PubMed ID: 8631003
[TBL] [Abstract][Full Text] [Related]
9. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma.
Takita J; Hayashi Y; Kohno T; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
Cancer Res; 1997 Mar; 57(5):907-12. PubMed ID: 9041193
[TBL] [Abstract][Full Text] [Related]
10. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
Pollock PM; Welch J; Hayward NK
Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
[TBL] [Abstract][Full Text] [Related]
11. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
13. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
14. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
16. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines.
Gonzalgo ML; Hayashida T; Bender CM; Pao MM; Tsai YC; Gonzales FA; Nguyen HD; Nguyen TT; Jones PA
Cancer Res; 1998 Mar; 58(6):1245-52. PubMed ID: 9515812
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
[TBL] [Abstract][Full Text] [Related]
18. [Biallelic inactivation of the p16-Gen in a metachronous triple carcinoma in the oropharyngeal region].
Motsch C; Giers A; Boltze C; Evert M; Freigang B; Roessner A; Schneider-Stock R
Laryngorhinootologie; 2004 Jan; 83(1):55-60. PubMed ID: 14740307
[TBL] [Abstract][Full Text] [Related]
19. Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain.
Zhang SJ; Endo S; Ichikawa T; Washiyama K; Kumanishi T
Cancer Res; 1998 Mar; 58(6):1231-7. PubMed ID: 9515810
[TBL] [Abstract][Full Text] [Related]
20. High frequency of p16INK4A gene alterations in hepatocellular carcinoma.
Liew CT; Li HM; Lo KW; Leow CK; Chan JY; Hin LY; Lau WY; Lai PB; Lim BK; Huang J; Leung WT; Wu S; Lee JC
Oncogene; 1999 Jan; 18(3):789-95. PubMed ID: 9989830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
